🇺🇸 FDA
Pipeline program

Psilocybin

COMP001

Phase 3 small_molecule active

Quick answer

Psilocybin for Treatment Resistant Depression is a Phase 3 program (small_molecule) at Compass Therapeutics with 7 ClinicalTrials.gov record(s).

Program details

Company
Compass Therapeutics
Indication
Treatment Resistant Depression
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials